{
    "nct_id": "NCT06268886",
    "title": "A Randomized, Double-blind, Placebo-controlled, Global Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease (TargetTau-1)",
    "status": "ACTIVE_NOT_RECRUITING",
    "last_update_time": "2025-07-21",
    "description_brief": "The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted biologic",
    "drug": [
        "BMS-986446 (humanized monoclonal antibody; anti\u2011MTBR tau)",
        "PRX005 (alias referenced in partner press materials)"
    ],
    "placebo": [
        "placebo (randomized placebo\u2011controlled comparator)"
    ],
    "explanation_target": [
        "Reason: The investigational agent, BMS-986446, is a humanized monoclonal antibody that binds the microtubule\u2011binding region (MTBR) of tau to neutralize intercellular tau spread and promote clearance \u2014 i.e., it targets pathological tau biology with the goal of modifying disease progression. \ue200cite\ue202turn0search0\ue202turn0search2\ue201",
        "Act: Key trial details \u2014 TargetTau\u20111 (NCT06268886) is a randomized, double\u2011blind, placebo\u2011controlled Phase 2 proof\u2011of\u2011concept study in participants with early Alzheimer\u2019s disease evaluating multiple doses of BMS\u2011986446; the protocol and sponsor (Bristol\u2011Myers Squibb) describe the antibody and its disease\u2011modifying intent. \ue200cite\ue202turn0search4\ue202turn0search2\ue201",
        "Act (additional source): Sponsor and partner press releases and site trial pages describe preclinical effects (reduced tau uptake/spread, microglial Fc\u2011mediated clearance) and Phase 1 tolerability, supporting that this is a biologic directed at AD pathology (sometimes referenced as PRX005 in partner materials). \ue200cite\ue202turn0search3\ue202turn0search0\ue201",
        "Reflect: Matching to category definitions \u2014 because BMS\u2011986446 is a monoclonal antibody (a biologic) that specifically targets Alzheimer\u2019s pathology (MTBR tau) and is being tested to alter disease course, the correct classification is 'disease\u2011targeted biologic'. The study is placebo\u2011controlled (placebo listed as comparator). \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Web search sources used (key results cited above): Bristol Myers Squibb corporate release on BMS\u2011986446; TargetTau\u20111 design article (PMCID) describing the Phase 2 trial; BMS clinical trials / NCT06268886 registry information; partner (Prothena) press release; Yale trial listing. \ue200cite\ue202turn0search0\ue202turn0search2\ue202turn0search4\ue202turn0search3\ue202turn0search1\ue201"
    ],
    "agent_type": "B) Tau",
    "explanation_agent": [
        "Reason: The investigational agent BMS-986446 (also referenced as PRX005) is a humanized monoclonal antibody that binds the microtubule\u2011binding region (MTBR) of tau to neutralize cell\u2011to\u2011cell tau spread and promote clearance (including Fc\u2011mediated microglial clearance) \u2014 i.e., it specifically targets pathological tau biology, which maps directly to CADRO category B (Tau). \ue200cite\ue202turn0search1\ue202turn0search4\ue201.",
        "Act: Extracted trial details and evidence \u2014 TargetTau\u20111 (NCT06268886) is a randomized, double\u2011blind, placebo\u2011controlled Phase 2 proof\u2011of\u2011concept study sponsored by Bristol Myers Squibb evaluating multiple doses of BMS\u2011986446 in participants with early Alzheimer\u2019s disease; the program materials and partner releases explicitly describe BMS\u2011986446/PRX005 as an anti\u2011MTBR tau monoclonal antibody with disease\u2011modifying intent. \ue200cite\ue202turn0search3\ue202turn0search1\ue202turn0search4\ue201.",
        "Reflect: Classification check \u2014 because the drug is a monoclonal antibody directed at pathological tau (MTBR) and the trial\u2019s stated goal is to alter disease progression by reducing tau spread/clearing tau, the correct CADRO classification is B) Tau. This is not multi\u2011target (R) nor a non\u2011therapeutic study (T), so B) Tau is the most specific fit.",
        "Web search results used (key sources cited above):",
        "- Bristol Myers Squibb press release describing BMS\u2011986446 (anti\u2011MTBR\u2011tau), mechanism (binds R1\u2013R3 MTBR, prevents cell\u2011to\u2011cell spread, activates microglial Fc clearance) and TargetTau\u20111 Phase 2 details. \ue200cite\ue202turn0search1\ue201.",
        "- Prothena / partner press release noting PRX005 / BMS\u2011986446 anti\u2011MTBR\u2011tau program and license/opt\u2011in history. \ue200cite\ue202turn0search4\ue201.",
        "- Prothena investor/partner release reporting Fast Track designation and preclinical/Phase 1 observations (reduced tau uptake/spread; Phase 1 tolerability). \ue200cite\ue202turn0search0\ue201.",
        "- ClinicalTrials listing for NCT06268886 (TargetTau\u20111) with Phase 2 designation, randomized double\u2011blind placebo\u2011controlled design and sponsor information. \ue200cite\ue202turn0search3\ue201."
    ]
}